Arbutus Biopharma ABUS
NASDAQ ABUS
$5.15 +0.03 (+0.59%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arbutus Biopharma (ABUS) EV to EBIT (2013 - 2026)

Analysis

Arbutus Biopharma (ABUS) EV to EBIT (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Arbutus Biopharma 1.02 Bn 927.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -143.53
Mar 31, 2026 4.68
Dec 31, 2025 -157.77
Sep 30, 2025 -89.82
Jun 30, 2025 332.05
Mar 31, 2025 -21.62
Dec 31, 2024 -35.78
Sep 30, 2024 -28.06
Jun 30, 2024 -20.44
Mar 31, 2024 -17.33
Dec 31, 2023 -14.40
Sep 30, 2023 -9.57
Jun 30, 2023 -12.59
Mar 31, 2023 -20.31
Dec 31, 2022 -9.75
Sep 30, 2022 -8.81
Jun 30, 2022 -17.93
Mar 31, 2022 -25.31
Dec 31, 2021 -12.40
Sep 30, 2021 -19.10